Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing-Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Patti, Francesco ^a   Morra, Vincenzo Brescia ^b   Amato, Maria Pia ^c   Trojano, Maria ^d   Bastianello, Stefano ^e   Tola, Maria Rosalia ^f   Cottone, Salvatore ^g   Plant, Andrea ^h   Picconi, Orietta ⁱ  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^g Centro Di Riferimento Regionale di Neuroimmunologia   (Italy)

^h Caudex Medical   (United Kingdom)

ⁱ Opera CRO Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON;

ADULT; ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; DEPRESSION; DISABILITY SEVERITY; DRUG DOSE COMPARISON; DRUG RESPONSE; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PROGNOSIS; PROSPECTIVE STUDY; SEX DIFFERENCE;

ADOLESCENT; ADULT; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; RECURRENCE; SAFETY; SEX CHARACTERISTICS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84883416256     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074111     Document Type: Article

References (41)

1. Rao SM, (1995) Neuropsychology of multiple sclerosis. Curr Opin Neurol 8: 216-220.
2. Patti F, (2009) Cognitive impairment in multiple sclerosis. Mult Scler 15: 2-8.
3. Achiron A, Polliack M, Rao SM, Barak Y, Lavie M, et al. (2005) Cognitive patterns and progression in multiple sclerosis: construction and validation of percentile curves. J Neurol Neurosurg Psychiatry 76: 744-749.
4. Rogers JM, Panegyres PK, (2007) Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations. J Clin Neurosci 14: 919-927.
5. Lynch SG, Parmenter BA, Denney DR, (2005) The association between cognitive impairment and physical disability in multiple sclerosis. Mult Scler 11: 469-476.
6. Amato MP, Ponziani G, Siracusa G, Sorbi S, (2001) Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 58: 1602-1606.
7. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, et al. (1991) Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 41: 692-696.
8. Ruet A, Deloire M, Hamel D, Ouallet JC, Petry K, et al. (2012) Cognitive impairment, health-related quality of life and vocational status at early stages of multiple sclerosis: a 7-year longitudinal study. J Neurol Oct 19 [Epub ahead of print]: 10.1007/s00415-012-6705-1.
9. Barak Y, Achiron A, (2006) Cognitive fatigue in multiple sclerosis: findings from a two-wave screening project. J Neurol Sci 245: 73-76.
10. Ghaffar O, Feinstein A, (2007) The neuropsychiatry of multiple sclerosis: a review of recent developments. Curr Opin Psychiatry 20: 278-285.
11. Bagert B, Camplair P, Bourdette D, (2002) Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management. CNS Drugs 16: 445-455.
12. Amato MP, Portaccio E, Zipoli V, (2006) Are there protective treatments for cognitive decline in MS? J Neurol Sci 245: 183-186.
13. Patti F, (2012) Treatment of cognitive impairment in patients with multiple sclerosis. Expert Opin Investig Drugs 21: 1679-1699.
14. Freedman MS, (2006) Disease-modifying drugs for multiple sclerosis: current and future aspects. Expert Opin Pharmacother 7(Suppl 1): S1-S9.
15. Amato MP, Portaccio E, Goretti B, Zipoli V, Ricchiuti L, et al. (2006) The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. Mult Scler 12: 787-793.
16. Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, et al. (2010) Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler 16: 68-77.
17. Patti F, Amato M, Trojano M, Bastianello S, Tola M, et al. (2009) Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult Scler 15: 779-788.
18. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56: 1628-1636.
19. Reuter F, Zaaraoui W, Crespy L, Faivre A, Rico A, et al. (2010) Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis. J Neurol Neurosurg Psychiatry 82: 1157-1159.
20. Glanz BI, Healy BC, Hviid LE, Chitnis T, Weiner HL, (2012) Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry 83: 38-43.
21. Duque B, Sepulcre J, Bejarano B, Samaranch L, Pastor P, et al. (2008) Memory decline evolves independently of disease activity in MS. Mult Scler 14: 947-953.
22. Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, et al. (2009) Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 66: 1144-1150.
23. Calabrese M, Bernardi V, Atzori M, Mattisi I, Favaretto A, et al. (2012) Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult Scler 18: 418-424.
24. Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, et al. (2006) Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin Immunol 118: 77-82.
25. Lindquist S, Hassinger S, Lindquist JA, Sailer M, (2011) The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment. Mult Scler 17: 851-866.
26. Alonso A, Hernan MA, (2008) Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71: 129-135.
27. Beeson PB, (1994) Age and sex associations of 40 autoimmune diseases. Am J Med 96: 457-462.
28. Hawkins SA, McDonnell GV, (1999) Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 67: 148-152.
29. Confavreux C, Vukusic S, Adeleine P, (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126: 770-782.
30. Pozzilli C, Tomassini V, Marinelli F, Paolillo A, Gasperini C, et al. (2003) 'Gender gap' in multiple sclerosis: magnetic resonance imaging evidence. Eur J Neurol 10: 95-97.
31. Weatherby SJ, Mann CL, Davies MB, Fryer AA, Hag N, et al. (2000) A pilot study of the relationship between gadolinium-enhancing lesions, gender effect and polymorphisms of antioxidant enzymes in multiple sclerosis. J Neurol 247: 467-470.
32. Hensiek AE, Sawcer SJ, Feakes R, Deans J, Mander A, et al. (2002) HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 72: 184-187.
33. Celius EG, Harbo HF, Egeland T, Vartdal F, Vandvik B, et al. (2000) Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci 178: 132-135.
34. Tomassini V, Onesti E, Mainero C, Giugni E, Paolillo A, et al. (2005) Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry 76: 272-275.
35. Kipp M, Amor S, Krauth R, Beyer C, (2012) Multiple sclerosis: neuroprotective alliance of estrogen-progesterone and gender. Front Neuroendocrinol 33: 1-16.
36. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T, et al. (1998) Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 339: 285-291.
37. Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, et al. (2004) Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 127: 1353-1360.
38. Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, et al. (2009) Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. J Neurol Sci 286: 109-113.
39. Rudick RA, Kappos L, Kinkel R, Clanet M, Phillips JT, et al. (2011) Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients. Mult Scler 17: 353-360.
40. Kujala P, Portin R, Ruutiainen J, (1997) The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain 120: 289-297.
41. Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, et al. (2004) Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 364: 1489-1496.